ATE196255T1 - Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen. - Google Patents

Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen.

Info

Publication number
ATE196255T1
ATE196255T1 AT96906795T AT96906795T ATE196255T1 AT E196255 T1 ATE196255 T1 AT E196255T1 AT 96906795 T AT96906795 T AT 96906795T AT 96906795 T AT96906795 T AT 96906795T AT E196255 T1 ATE196255 T1 AT E196255T1
Authority
AT
Austria
Prior art keywords
antibodies
regulatory protein
pct
immunogene
production
Prior art date
Application number
AT96906795T
Other languages
English (en)
Inventor
Jean-Francois Zagury
Bernard Bizzini
Daniel Zagury
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26231806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE196255(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9502708A external-priority patent/FR2731355B1/fr
Application filed by Neovacs filed Critical Neovacs
Application granted granted Critical
Publication of ATE196255T1 publication Critical patent/ATE196255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96906795T 1995-03-08 1996-03-07 Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen. ATE196255T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9502708A FR2731355B1 (fr) 1995-03-08 1995-03-08 Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant
PCT/FR1996/000357 WO1996027389A1 (fr) 1995-03-08 1996-03-07 Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps, procede de preparation et compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
ATE196255T1 true ATE196255T1 (de) 2000-09-15

Family

ID=26231806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96906795T ATE196255T1 (de) 1995-03-08 1996-03-07 Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen.

Country Status (12)

Country Link
US (1) US6132721A (de)
EP (1) EP0814834B2 (de)
JP (1) JPH11501310A (de)
AT (1) ATE196255T1 (de)
AU (1) AU710626B2 (de)
BR (1) BR9607659A (de)
CA (1) CA2215483C (de)
DE (1) DE69610295T3 (de)
DK (1) DK0814834T4 (de)
GR (1) GR3034970T3 (de)
PL (1) PL322143A1 (de)
WO (1) WO1996027389A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
FR2773156B1 (fr) * 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
FR2781158B1 (fr) 1998-07-15 2002-12-13 Vacs Internat Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
FR2792206B1 (fr) * 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
ATE465754T1 (de) * 1999-08-12 2010-05-15 Inist Inc Nicht-immunsuppresives hiv tat-protein
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
FR2802426B1 (fr) 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
BR0107972A (pt) * 2000-01-31 2002-11-05 Smithkline Beecham Biologicals Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
AU2002358181A1 (en) * 2001-12-11 2003-07-09 Aventis Pasteur Mutated hiv tat
US7588764B2 (en) * 2002-03-01 2009-09-15 University Of Kentucky Research Foundation Compositions comprising human immunodeficiency virus Tat adsorbed to the surface of anionic nanoparticles
FR2844514B1 (fr) 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US7927580B2 (en) 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
EP2411043B1 (de) 2009-03-23 2013-07-31 PIN Pharma, Inc. Krebsbehandlung mit immunstimulierenden hiv-tat-derivat-polypeptiden
CN105705164A (zh) 2013-10-04 2016-06-22 品诺制药公司 用于癌症治疗的免疫刺激性hiv tat衍生多肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2227861B1 (de) † 1973-05-04 1976-07-02 Anvar
EP0330359A3 (de) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Zusammensetzung, verwendbar zur Diagnose und Behandlung von HIV-I-Infektion
AU3756789A (en) * 1988-06-16 1990-01-12 St. Louis University Antagonists of viral transactivating proteins
AU7677891A (en) * 1990-03-30 1991-10-30 Smithkline Beecham Corporation Inhibition of disease associated with immunodeficiency virus infection
WO1991018454A1 (en) * 1990-05-18 1991-11-28 Centre National De La Recherche Scientifique Compositions capable of blocking cytotoxicity of viral regulatory proteins and neurotoxic symptoms associated with retroviral infection
JPH06508603A (ja) * 1991-02-14 1994-09-29 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション ＨＩＶ　Ｔａｔタンパク質に対する新規インテグリン特異性
WO1993022349A1 (en) * 1992-04-24 1993-11-11 The Institute For Human Genetics And Biochemistry NATURAL HUMAN IgM ANTIBODIES
WO1993025235A1 (en) * 1992-06-09 1993-12-23 President And Fellows Of Harvard College Aids therapeutics based on hiv-2 vpx peptides
WO1994015634A1 (en) * 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
AU7263994A (en) * 1993-08-06 1995-02-28 Kai Juhani Ernst Krohn Novel mutated human and simian immunodeficiency viruses and vaccines containing said viruses

Also Published As

Publication number Publication date
DK0814834T4 (da) 2009-07-20
EP0814834B2 (de) 2009-03-18
DE69610295D1 (de) 2000-10-19
CA2215483C (fr) 2012-01-03
JPH11501310A (ja) 1999-02-02
DE69610295T3 (de) 2009-10-08
GR3034970T3 (en) 2001-02-28
DE69610295T2 (de) 2001-02-22
EP0814834B1 (de) 2000-09-13
AU710626B2 (en) 1999-09-23
CA2215483A1 (fr) 1996-09-12
BR9607659A (pt) 1998-12-15
WO1996027389A1 (fr) 1996-09-12
DK0814834T3 (da) 2000-11-13
EP0814834A1 (de) 1998-01-07
AU5007196A (en) 1996-09-23
PL322143A1 (en) 1998-01-05
US6132721A (en) 2000-10-17

Similar Documents

Publication Publication Date Title
ATE196255T1 (de) Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen.
DE59607548D1 (de) Verfahren zur herstellung von morphologisch einheitlichen mikrokapseln sowie nach diesem verfahren hergestellte mikrokapseln
DE69508192D1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
FI972093A0 (fi) Jäteveden käsittelymenetelmä ja -laitos
ATE204162T1 (de) Verfahren zur herstellung von wirkstoffzubereitungen in form einer festen lösung des wirkstoffs in einer polymermatrix
ATE316100T1 (de) Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
RU94017851A (ru) Ингибиторы протеолитических ферментов на основе производных сахарина, фармацевтическая композиция для лечения дегеративных заболеваний
PT99892A (pt) Processo para a producao de microparticulas carregadas de substancia activa a partir de polimeros que se decompoem hidroliticamente
DK0790824T3 (da) 2,2-dichloralkancarboxylsyrer, fremgangsmåde til fremstilling deraf, lægemidler indeholdende disse og anvendelse af disse lægemidler til behandling af insulinresistens
ATE157879T1 (de) Transformierte erythrozyten, verfahren zu deren herstellung, und ihre verwendung in pharmazeutischen zusammensetzungen
NO980163L (no) Renset, varmekoagulert potetprotein for anvendelse i dyrefôr
DE3773077D1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATE213231T1 (de) Michellamine zur verwendung als antivirale wirkstoffe, zusammensetzung und behandlungsverfahren
ATE111455T1 (de) 3-substituierte 1,2,3,4-oxatriazol-5- iminderivate, verfahren zur herstellung sowie diese enthaltende arzneimittel.
DE59006295D1 (de) Verfahren zur Herstellung perfluorierter heterocyclischer Verbindungen und nach diesem Verfahren hergestellte Verbindungen.
ATE190492T1 (de) Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren
DE60335892D1 (de) Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung und/oder fettleibigkeit im zusammenhang steht
ATE238988T1 (de) Als verknüpfungsreagenzien einsetzbare dimaleinimidosubstituierte dihydroxyalkane und verfahren zu deren herstellung
MD950010A (ro) Compoziţie pentru înlăturarea sau dezactivarea componentelor dăunătoare în sînge sau alte lichide extracelulare ale organismului şi procedeu de obţinere
KR920008035A (ko) 타이로신 유도체 및 그 제조방법
KR880009644A (ko) 궤양성 대장질환 치료용 약한 조성물
ATE78833T1 (de) Derivat von d.25, verfahren zur herstellung, verwendung als immunostimulierendes mittel und pharmazeutische zusammensetzungen, welche diese enthalten.
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
DE68917110D1 (de) Fluorierte Gelatine und Verfahren zu deren Herstellung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties